Pharmaceutical Technology

JUNE 20, 2025

Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Data Insights The gold standard of business intelligence. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Insurance Coverage and Processing 52

Insurance Coverage and Processing Hospitals Communication Pharmaceutical Manufacturing 52

Pharmaceutical Technology

JULY 3, 2025

It comes with one for cytokine release syndrome (CRS) and neurologic toxicity – including immune effector cell-associated neurotoxicity syndrome – in addition to warnings and precautions for infections, neutropenia, hepatotoxicity and embryo-foetal toxicity.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 1, 2025

A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an ‘immune reset’ by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62

Insurance Coverage and Processing 52

Insurance Coverage and Processing Packaging Communication Hospitals 52

Pharmaceutical Technology

JULY 8, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Data Insights The gold standard of business intelligence.

Immunity 52

Immunity Immunization Packaging Hospitals 52

Pharmaceutical Technology

JULY 14, 2025

A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. That is instead recommended by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).

Labelling 52

Labelling Vaccines Insurance Coverage and Processing Packaging 52

Pharmaceutical Technology

JUNE 11, 2025

CD4+T-cells and lymphocytes are both crucial elements of the immune system. The FDA placed a hold on the trials due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the GS-1720 and GS-4182 combination.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Communication Hospitals Packaging 52

Pharmaceutical Technology

JUNE 18, 2025

fired 17 sitting members of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC), concerns rose about the stance of federal agencies on vaccines.

Vaccines 52

Vaccines Communication Hospitals Drug Development 52

Pharmaceutical Technology

JULY 11, 2025

Its design minimises interaction with Fc-gamma (Fcγ) receptors on macrophages, enhancing the ability of the body’s immune cells to recognise and combat tumours.

Packaging 52

Packaging Hospitals Biosimilars Communication 52

Pharmaceutical Technology

JULY 15, 2025

LaNova’s drug development focuses on tumour immunity and the tumour microenvironment. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Packaging 75

Packaging Communication Hospitals Drug Development 75

Pharmaceutical Technology

JUNE 16, 2025

Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing standards of care for treating certain patients with locally advanced HNSCC.”

Communication 52

Communication Research Laboratories Hospitals Vaccines 52

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Find out more Sign up for our daily news round-up!

Hospitals 52

Hospitals Packaging Communication Immunity 52

pharmaphorum

JULY 17, 2025

Skip to main content Thursday 17 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Immunity 52

Immunity Immunization Diabetes Pharmaceutical Companies 52

Pharmaceutical Technology

JULY 15, 2025

LEO’s new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor – a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. It has also been approved in expanded indications in GPP in certain territories.

Packaging 52

Packaging Communication Hospitals Vaccines 52

Pharmaceutical Technology

JUNE 13, 2025

This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. The expanded approval now includes individuals aged 18 to 59 who are at risk of RSV.

Vaccines 52

Vaccines Insurance Coverage and Processing Labelling Communication 52

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

Pharmaceutical Technology

JUNE 10, 2025

The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) in a move observers warn is liable to further fuel the spread of vaccine-preventable illnesses. lev radin via Shutterstock.

Vaccines 52

Vaccines Insurance Coverage and Processing Drug Pricing Immunity 52

Pharmaceutical Technology

JUNE 12, 2025

By GlobalData Learn more about Strategic Intelligence By covering a wide range of targets on malignant B cells, the therapy aims to enhance safety and efficacy while minimising the potential of tumour cells for developing immune-resistance mechanisms such as antigen escape.

Communication 52

Communication Hospitals Packaging Immunity 52

Pharmaceutical Technology

JUNE 25, 2025

In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety.

Vaccines 52

Vaccines Packaging Hospitals Communication 52

Pharmaceutical Technology

JUNE 25, 2025

RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease.

Vaccines 116

Vaccines Hospitals Packaging Communication 116

pharmaphorum

JULY 17, 2025

Skip to main content Thursday 17 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Immunity 52

Immunity Immunization Diabetes Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 16, 2025

A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. Two patients experienced dose-limiting toxicities and continued to receive the targeted dose.

Labelling 52

Labelling Communication Hospitals Vaccines 52

pharmaphorum

JULY 18, 2025

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 52

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines 72

Vaccines Diabetes Pharmaceutical Companies Pharmaceutical Companies 72

pharmaphorum

JULY 1, 2025

billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio. billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio.

Diabetes 66

Diabetes Pharmaceutical Companies Pharmaceutical Companies Immunity 66

Pharmaceutical Technology

MARCH 20, 2023

The collaboration, under a sponsored research agreement, will focus on mRNA vaccines that can help in modulating the normal immune response of the body for the treatment of certain autoimmune diseases as well as allergic conditions. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines 98

Vaccines Immunity Immunization Communication 98

Pharmaceutical Technology

DECEMBER 8, 2022

Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Communication 122

Communication Immunity Immunization Hospitals 122

Pharmaceutical Technology

JANUARY 17, 2023

CAR-T therapies are based on the patient’s immune cell modification and can express artificial chimeric receptors that can identify and remove tumour cells. This therapy is expected to be an improvement over CAR-T in relapsed patients, especially those who have less number of normal T lymphocytes.

Hospitals 110

Hospitals Chemotherapy Communication Immunity 110

Pharmaceutical Technology

JANUARY 10, 2023

The collaboration will combine 3T Biosciences’ 3T- T-Cell Receptor Antigen and Cross-Reactivity Engine (TRACE) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining compounds that are directed towards cancer cells and target immune cells.

Immunity 52

Immunity Immunization Compounding Communication 52

FDA Law Blog: Biosimilars

APRIL 8, 2024

It also noted that last year, FDA hosted a two-day public workshop and published a white paper on the regulatory framework for Artificial Intelligence in drug manufacturing, in addition to other efforts. Like many of us, OPQ seems intent on trying to keep up with how technology can/will impact pharmaceutical quality.

Immunity 59

Immunity Immunization 59

Pharmaceutical Technology

JANUARY 27, 2023

It takes own immune cells of a patient and modifies them to attach and destroy cancer cells. The new CAR-T therapy will be given as a one-off intravenous infusion. Previously, it was available through the Cancer Drugs Fund (CDF).

Communication 59

Communication Immunity Immunization 59

Pharmaceutical Technology

FEBRUARY 28, 2023

It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune. The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials.

Immunity 52

Immunity Immunization Communication Drug Development 52

Pharmaceutical Technology

DECEMBER 7, 2022

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment.

Drug Development 105

Drug Development Communication Immunity Immunization 105

Pharmaceutical Technology

MARCH 1, 2023

PLpro is the second coronavirus protease responsible for suppressing the human immune system, causing more severe Covid-19. The licensed technology specifically includes small molecules found to be efficient PLpro inhibitors.

Communication 59

Communication Immunity Immunization 59

Pharmaceutical Technology

DECEMBER 7, 2022

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment.

Drug Development 98

Drug Development Communication Immunity Immunization 98

Pharmaceutical Technology

MARCH 9, 2023

UCB4594 targets the immune checkpoint, human leukocyte antigen G, which is also called HLA-G. If the clinical trials are successful, these candidates might have the potential to provide access to new targeted treatment options for cancer patients.

Communication 52

Communication Immunity Immunization Drug Development 52

Pharmaceutical Technology

MAY 4, 2023

To find out more about Pall’s specialist filters and the services available in water safety, download the white paper on this page. While NTMs can affect anyone, patients with weakened immune systems or existing lung problems are at the highest risk of developing more serious diseases from infection.

Hospitals 52

Hospitals Documentation Communication Immunity 52

Quality Matters

FEBRUARY 9, 2023

Next steps to expand capacity Reducing vaccine inequities across Africa, whether for COVID-19, Ebola , Mpox , or routine immunizations, requires reducing reliance on imported products by building strong partnerships across multiple sectors, including government regulatory agencies.

Vaccines 52

Vaccines Immunity Immunization Labelling 52